AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24717624 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution CT classified as inconsistent with usual interstitial pneumonia
Number of subjects: 315
Study 24717623 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower respiratory consultations (infective and non-infective)
Number of subjects: 38859
Study 24717623 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower respiratory consultations with a course of antibiotics or oral steroids
Number of subjects: 38859
Study 24717623 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiography
Number of subjects: 38859
Study 24717623 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at diagnosis
Number of subjects: 38859
Study 24717623 — intervention group
Group type: EXPERIMENTAL
Intervention: Yearly frequency of lower respiratory prescribing consultations
Number of subjects: 38859
Study 24717623 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of comorbidities at COPD diagnosis
Number of subjects: 38859
Study 24717623 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiography and spirometry
Number of subjects: 38859
Study 24718643 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 24719405 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2-diphtheria fusion protein (IL2DT)
Number of subjects: 57
Study 24720836 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) rituximab
Number of subjects: 3
Study 24720836 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) rituximab
Number of subjects: 3
Study 24720900 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically modified dendritic cells in combination with Cytokine-Induced Killer Cell treatment (gmDCs-CIK)
Number of subjects: 28
Study 24721145 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFAs)
Number of subjects: 676
Study 24721145 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6)
Number of subjects: 676
Study 24721145 — intervention group
Group type: EXPERIMENTAL
Intervention: Low n-3 PUFA group
Number of subjects: 676
Study 24721145 — intervention group
Group type: EXPERIMENTAL
Intervention: Low n-3/n-6 PUFA group
Number of subjects: 676
Study 24721145 — intervention group
Group type: EXPERIMENTAL
Intervention: Low total PUFA group
Number of subjects: 676
Study 24721422 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 706
Study 24721422 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 706
Study 24721422 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 706
Study 24721422 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line TNFi (Adalimumab)
Number of subjects: 706
Study 24721422 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line TNFi (Etanercept)
Number of subjects: 706
Study 24721422 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line TNFi (Infliximab)
Number of subjects: 706
Study 24721691 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported indicators of periodontal disease (PD)
Number of subjects: 15828
Study 24721691 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth loss
Number of subjects: 15828
Study 24721691 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum bleeding
Number of subjects: 15828
Study 24721800 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propranolol and atropine
Number of subjects: 73
Study 24722180 — intervention group
Group type: EXPERIMENTAL
Intervention: High testosterone level (above median TL of 11.5 ng/dl), n=52
Number of subjects: 101
Study 24722180 — intervention group
Group type: COMPARATOR
Intervention: Low testosterone level (below median TL of 11.5 ng/dl), n=49
Number of subjects: 101
Study 24722180 — intervention group
Group type: COMPARATOR
Intervention: Presence of anaemia
Number of subjects: 101
Study 24722180 — intervention group
Group type: COMPARATOR
Intervention: Patients with both anaemia and low testosterone
Number of subjects: 101
Study 24722180 — intervention group
Group type: EXPERIMENTAL
Intervention: High testosterone level (above median TL of 11.5 ng/dl) receiving salvage hormonal therapy (SHT)
Number of subjects: 101
Study 24722180 — intervention group
Group type: COMPARATOR
Intervention: Low testosterone level (below median TL of 11.5 ng/dl) receiving salvage hormonal therapy (SHT)
Number of subjects: 101
Study 24722222 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults younger than 55 years with severe burn injuries and inhalation injury
Number of subjects: 541
Study 24722222 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults aged 55 years and older
Number of subjects: 541
Study 24722222 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients younger than 17 years
Number of subjects: 541
Study 24722222 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 541
Study 24722322 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler assessment of respirophasic ΔVpeak-CA
Number of subjects: 40
Study 24722322 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse pressure variation (PPV)
Number of subjects: 40
Study 24722322 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of ΔVpeak-CA in patients with pulse pressure hypertension (≥ 60 mm Hg)
Number of subjects: 40
Study 24722322 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of PPV in patients with pulse pressure hypertension (≥ 60 mm Hg)
Number of subjects: 40
Study 24722393 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocktail alone (session 1)
Number of subjects: 10
Study 24722393 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocktail with fluvoxamine and voriconazole (session 2)
Number of subjects: 10
Study 24722393 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocktail with quinidine (session 3)
Number of subjects: 10
Study 24722393 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocktail after 7-day pretreatment with rifampicin (session 4)
Number of subjects: 10
Study 24722393 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive one- and three-point DBS-sampling methods
Number of subjects: 10
Study 24723023 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical nomogram based on four independent factors (previous laparotomies, anatomical site of operation, presence of bowel fistula, laparotomy via pre-existing median scar)
Number of subjects: 715
Study 24723023 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadvertent bowel injury during adhesiolysis
Number of subjects: 715
Study 24723023 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel resection required for enterotomies
Number of subjects: 715
Study 24723284 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 319
Study 24723428 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) for patients with comorbid GERD (n = 72)
Number of subjects: 229
Study 24723428 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sinus surgery (ESS) for patients without GERD (n = 157)
Number of subjects: 229
Study 24723428 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medical therapy for GERD (n = 49)
Number of subjects: 229
Study 24723493 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentostatin, alemtuzumab, and low-dose high-frequency rituximab
Number of subjects: 39
Study 24723493 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rituximab
Number of subjects: 39
Study 24723677 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose plerixafor treatment
Number of subjects: 0
Study 24725395 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuIL-12 at doses of 2, 5, 10, 12, and 15 μg; 20 μg in the FIH study; 12 μg in the phase 1b expansion study.
Number of subjects: 92
Study 24725395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 24725582 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 918
Study 24725582 — intervention group
Group type: COMPARATOR
Intervention: Intubation/Surfactant
Number of subjects: 918
Study 24725582 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 918
Study 24725803 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart (IAsp)
Number of subjects: 19
Study 24725803 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin (HI)
Number of subjects: 19
Study 24725803 — intervention group
Group type: COMPARATOR
Intervention: BIAsp70
Number of subjects: 19
Study 24725803 — intervention group
Group type: COMPARATOR
Intervention: BIAsp50
Number of subjects: 19
Study 24725803 — intervention group
Group type: EXPERIMENTAL
Intervention: All insulin preparations
Number of subjects: 19
Study 24725803 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive IGF
Number of subjects: 19
Study 24725832 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative BNP levels
Number of subjects: 277
Study 24725832 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative BNP levels
Number of subjects: 277
Study 24725992 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D culture
Number of subjects: 0
Study 24725992 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA mimics (hsa-miR-146b-5p and hsa-miR-99a)
Number of subjects: 0
Study 24725992 — intervention group
Group type: EXPERIMENTAL
Intervention: Downregulated miRNAs
Number of subjects: 0
Study 24725992 — intervention group
Group type: EXPERIMENTAL
Intervention: hsa-miR-302a, hsa-miR-182, hsa-miR-7, hsa-miR-20a/b, hsa-miR-17
Number of subjects: 0
Study 24725992 — intervention group
Group type: EXPERIMENTAL
Intervention: hsa-miR-96
Number of subjects: 0
Study 24725992 — intervention group
Group type: EXPERIMENTAL
Intervention: hsa-miR-7 and hsa-miR-17
Number of subjects: 0
Study 24726012 — intervention group
Group type: EXPERIMENTAL
Intervention: MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein)
Number of subjects: 12
Study 24726012 — intervention group
Group type: COMPARATOR
Intervention: Control group (MART-1 peptide vaccination without IMP321)
Number of subjects: 12
Study 24726214 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical embryo phenotypes (AS, A1(cyt), AC, CC)
Number of subjects: 67
Study 24726214 — intervention group
Group type: COMPARATOR
Intervention: Control embryos
Number of subjects: 67
Study 24726226 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS 13.5 mg
Number of subjects: 0
Study 24726226 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS 19.5 mg
Number of subjects: 0
Study 24726226 — intervention group
Group type: COMPARATOR
Intervention: LNG-IUS 20 μg/24 h
Number of subjects: 0
Study 24726248 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status and environmental factors (season)
Number of subjects: 203
Study 24726248 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, village, and time of visit
Number of subjects: 203
Study 24726253 — intervention group
Group type: EXPERIMENTAL
Intervention: LA emptying fraction measurement
Number of subjects: 0
Study 24726680 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg once daily for 7 days
Number of subjects: 30
Study 24726680 — intervention group
Group type: COMPARATOR
Intervention: HCTZ 25 mg once daily for 28 days
Number of subjects: 30
Study 24726680 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg + HCTZ 25 mg once daily for 7 days
Number of subjects: 30
Study 24726680 — intervention group
Group type: COMPARATOR
Intervention: Canagliflozin alone
Number of subjects: 30
Study 24726680 — intervention group
Group type: COMPARATOR
Intervention: HCTZ alone
Number of subjects: 30
Study 24726680 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin + HCTZ
Number of subjects: 30
Study 24727704 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative NT-proBNP≥1028 ng litre(-1)
Number of subjects: 365
Study 24727704 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroSCORE II
Number of subjects: 365
Study 24727704 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP≥1028 ng litre(-1) in intermediate-risk patients (EuroSCORE II 2.0-10.0)
Number of subjects: 365
Study 24728273 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Number of subjects: 20
Study 24728273 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet + Bevacizumab
Number of subjects: 20
Study 24728273 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 20
Study 24728331 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score based on four variables: tenderness of hand or foot joints, early morning stiffness ≥30 min, high-positive autoantibodies, and positive ultrasonographic power Doppler signal
Number of subjects: 100
Study 24728331 — intervention group
Group type: EXPERIMENTAL
Intervention: Low risk (score 0)
Number of subjects: 100
Study 24728331 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate risk (score 1-2)
Number of subjects: 100
Study 24728331 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk (score ≥3)
Number of subjects: 100
Study 24728331 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding shared epitope to risk score
Number of subjects: 100
Study 24728332 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging findings from the Osteoarthritis Initiative (OAI)
Number of subjects: 0
Study 24728332 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI findings on cartilage morphology, cartilage lesions and composition (T2), bone, meniscus, muscle and adipose tissue
Number of subjects: 0
Study 24728332 — intervention group
Group type: EXPERIMENTAL
Intervention: Public access to clinical and image data from OAI
Number of subjects: 0
Study 24728332 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term observations from OAI
Number of subjects: 0
Study 24728416 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 cups per day of instant caffeinated coffee
Number of subjects: 32
Study 24728416 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 32
Study 24728416 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 32
Study 24729079 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injections of ranibizumab
Number of subjects: 0
Study 24729519 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk adiponectin
Number of subjects: 118
Study 24729519 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk leptin
Number of subjects: 118
Study 24730732 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV-infected patients
Number of subjects: 461
Study 24730732 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/HCV-infected patients
Number of subjects: 461
Study 24730732 — intervention group
Group type: COMPARATOR
Intervention: HIV infection
Number of subjects: 461
Study 24730732 — intervention group
Group type: COMPARATOR
Intervention: Fib-4 score > 1.45
Number of subjects: 461
Study 24730732 — intervention group
Group type: COMPARATOR
Intervention: Hypovitaminosis D
Number of subjects: 461
Study 24730732 — intervention group
Group type: COMPARATOR
Intervention: HCV GT6
Number of subjects: 461
Study 24731226 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based salt reduction intervention based on the Communication for Behavioural Impact framework, duration 6-12 months.
Number of subjects: 0
Study 24731268 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 116
Study 24731816 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose schedule (Months 0 and 6)
Number of subjects: 0
Study 24731816 — intervention group
Group type: COMPARATOR
Intervention: Three-dose schedule (Months 0, 1, and 6)
Number of subjects: 0
Study 24732325 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose non-adjuvanted intradermal (ID) vaccine
Number of subjects: 450
Study 24732325 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose MF59-adjuvanted intramuscular (IM) vaccine
Number of subjects: 450
Study 24732325 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose MF59-adjuvanted IM vaccine
Number of subjects: 450
Study 24732325 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose non-adjuvanted ID vaccine
Number of subjects: 450
Study 24733029 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 61
Study 24733194 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual autopsy by multiphase PMCT angiography
Number of subjects: 143
Study 24733194 — intervention group
Group type: COMPARATOR
Intervention: Medical autopsy
Number of subjects: 143
Study 24733245 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (oral route, median dose of 10.0 mg/kg; range 3.4-11.4 mg/kg)
Number of subjects: 28
Study 24733245 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (oral route)
Number of subjects: 28
Study 24733463 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole i.v. 200 mg q.d.
Number of subjects: 66
Study 24733463 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole i.v. 300 mg q.d.
Number of subjects: 66
Study 24733463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 24733473 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP-21D9 (anthrax monoclonal antibody)
Number of subjects: 0
Study 24733796 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1) 3.6 mg/kg plus pertuzumab (840-mg loading dose, then 420 mg subsequently) every 3 weeks
Number of subjects: 64
Study 24733796 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1) plus pertuzumab
Number of subjects: 64
Study 24735977 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine iontophoresis (0.1 mA, 30s) at inter-electrode distance of 5 cm
Number of subjects: 14
Study 24735977 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine iontophoresis (0.1 mA, 30s) at inter-electrode distance of 10 cm
Number of subjects: 14
Study 24735977 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine iontophoresis (0.1 mA, 30s) at inter-electrode distance of 15 cm
Number of subjects: 14
Study 24735977 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine iontophoresis
Number of subjects: 14
Study 24736052 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical closure of macular hole
Number of subjects: 35
Study 24736094 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based, culturally congruent health-promotion intervention encouraging physical activity
Number of subjects: 1106
Study 24736094 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched HIV/STI risk-reduction control intervention
Number of subjects: 1106
Study 24737128 — intervention group
Group type: EXPERIMENTAL
Intervention: cMethDNA assay
Number of subjects: 29
Study 24737778 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivantinib 360 mg b.i.d. with gemcitabine 1000 mg/m(2) weekly for 3 of 4 weeks
Number of subjects: 29
Study 24737778 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivantinib 360 mg b.i.d. with gemcitabine
Number of subjects: 29
Study 24738612 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE MR imaging using parametric response map (PRM) analysis
Number of subjects: 48
Study 24738612 — intervention group
Group type: COMPARATOR
Intervention: Pharmacokinetic parameters (K(trans), kep, and ve)
Number of subjects: 48
Study 24738629 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin-loaded beads (2 mL drug-eluting beads; DC Bead 300-500 μm) at 5 mg
Number of subjects: 21
Study 24738629 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin-loaded beads (2 mL drug-eluting beads; DC Bead 300-500 μm) at 10 mg
Number of subjects: 21
Study 24738629 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin-loaded beads (2 mL drug-eluting beads; DC Bead 300-500 μm) at 15 mg
Number of subjects: 21
Study 24738629 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin-loaded beads (2 mL drug-eluting beads; DC Bead 300-500 μm)
Number of subjects: 21
Study 24738870 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic periodontitis in CKD patients
Number of subjects: 500
Study 24738870 — intervention group
Group type: COMPARATOR
Intervention: ADHS sample (control)
Number of subjects: 500
Study 24739099 — intervention group
Group type: EXPERIMENTAL
Intervention: Palaeolithic-type diet
Number of subjects: 12
Study 24739099 — intervention group
Group type: COMPARATOR
Intervention: Nordic Nutrition recommendations diet
Number of subjects: 12
Study 24739633 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly (I:C) TLR3 ligand stimulation in HT-29 cells
Number of subjects: 133
Study 24739633 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic biopsies from IBD patients
Number of subjects: 133
Study 24739633 — intervention group
Group type: EXPERIMENTAL
Intervention: Active IBD
Number of subjects: 133
Study 24739897 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg/day
Number of subjects: 67
Study 24739978 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadjuvanted cell culture-derived whole-virus H5N1 vaccine; two priming immunizations with clade 1 A/Vietnam H5N1 vaccine, booster with clade 2.1 A/Indonesia H5N1 vaccine 12 to 24 months later.
Number of subjects: 0
Study 24739978 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell responses assessed by ELISPOT in immunocompromised patients.
Number of subjects: 0
Study 24739978 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety and tolerability of the vaccine.
Number of subjects: 0
Study 24740809 — intervention group
Group type: EXPERIMENTAL
Intervention: Postinduction MRD level ≥10(-4)
Number of subjects: 423
Study 24740809 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfavorable genetic characteristics (MLL gene rearrangement or focal IKZF1 gene deletion in BCP-ALL; no NOTCH1/FBXW7 mutation and/or N/K-RAS mutation and/or PTEN gene alteration in T-cell ALL)
Number of subjects: 423
Study 24740992 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous non-invasive measurement using a finger cuff (MAPcNIAP)
Number of subjects: 120
Study 24740992 — intervention group
Group type: COMPARATOR
Intervention: Intermittent arm cuff oscillometry (MAPiNIAP)
Number of subjects: 120
Study 24741582 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab monotherapy (4 weekly doses)
Number of subjects: 25
Study 24741582 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab monotherapy followed by CHOP-21 (16 out of 25 patients)
Number of subjects: 25
Study 24742013 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 2313